Engineered bacteria for augmented in situ tumor vaccination

Xinyuan Shen; Chaojie Zhu; Xutao Liu; Hanqi Zheng; Qing Wu; Jijin Xie; Hao Huang; Ziyan Liao; Jiaqi Shi; Kewang Nan; Junxia Wang; Xuming Mao; Zhen Gu; Hongjun Li

doi:10.1039/D2BM01593E

Engineered bacteria for augmented in situ tumor vaccination

Xinyuan Shen,†^a Chaojie Zhu,

†^ab Xutao Liu,†^c Hanqi Zheng,^a Qing Wu,^ad Jijin Xie,^e Hao Huang,^f Ziyan Liao,^a Jiaqi Shi,^ad Kewang Nan,^g Junxia Wang,

^a Xuming Mao,

^e Zhen Gu

*^adhij and Hongjun Li

*^abd

Author affiliations

* Corresponding authors

^a Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
E-mail: guzhen@zju.edu.cn, hongjun@zju.edu.cn

^b Department of Hepatobiliary and Pancreatic Surgery the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China

^c Department of Bioengineering, University of California, Los Angeles, California 90095, USA

^d Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China

^e Institute of Pharmaceutical Biotechnology, School of Medicine, Zhejiang University, Hangzhou 310058, China

^f College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China

^g Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

^h Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China

ⁱ Jinhua Institute of Zhejiang University, Jinhua 321299, China

^j MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China

Abstract

In situ tumor vaccination has aroused tremendous interest with its capability for eliciting strong and systemic antitumor immune responses. Unlike traditional cancer vaccines, in situ tumor vaccination avoids the laborious process of tumor antigen identification and can modulate tumor immunosuppressive microenvironment at the same time. In recent years, bacteria have been used as both efficient tumor-targeted delivery vehicles and potent adjuvants. Regarding the rapid development in this area, in this review, we summarize recent advances in the application of bacteria for in situ cancer vaccination. We illustrate the mechanisms of bacteria as both efficient tumor immunogenic cell death inducers and tumor-targeted delivery platforms. Then we comprehensively review the engineering strategies for designing bacteria-based in situ vaccination, including chemical modification, nanotechnology, and genetic engineering. The current dilemma and future directions are discussed at the end of this review.

This article is part of the themed collection: Biomaterials Science 10th Anniversary Collection

Biomaterials Science

Engineered bacteria for augmented in situ tumor vaccination

Abstract

Article information

Download Citation

Permissions

Engineered bacteria for augmented in situ tumor vaccination

Social activity

Search articles by author

Spotlight

Advertisements